(NYSEMKT: SER) Serina Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.55%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.98%.
Serina Therapeutics's earnings in 2026 is -$19,436,000.On average, 2 Wall Street analysts forecast SER's earnings for 2026 to be -$17,536,594, with the lowest SER earnings forecast at -$17,015,705, and the highest SER earnings forecast at -$18,231,112. On average, 2 Wall Street analysts forecast SER's earnings for 2027 to be -$13,059,166, with the lowest SER earnings forecast at -$12,671,270, and the highest SER earnings forecast at -$13,576,360.
In 2028, SER is forecast to generate -$11,193,571 in earnings, with the lowest earnings forecast at -$10,861,088 and the highest earnings forecast at -$11,636,880.